Deep Genomics Nominates Industry’s First AI - Discovered Therapeutic Candidate
Summary
“This is an important milestone for patients affected by Wilson disease and it represents a significant advance in the drug discovery community more broadly,” said Brendan Frey, founder and CEO of Deep Genomics. “The clarity that this artificial intelligence platform has brought to the scientific community is astounding and the potential of a therapy that could operate at the genomic level to correct the disease process is exciting. “Our expectation is that, going forward, Deep Genomics’ platform will enable them to go from known target to first patient dosed in less than half the time of the industry standard, and they may be able to do this even faster with subsequent programs,” said Arthur A. Levin, Ph.D., a member of the company’s Strategic Advisory Board. Developing new therapeutics is full of unknowns, but I am certain that we are witnessing a new era of drug discovery.” Wilson disease can be caused by several different mutations that lead to loss of a protein required for copper transport (ATP7B). Without the necessary protein, copper is improperly regulated in the body and accumulates at toxic levels in the liver and central nervous system, leading to hepatic, neurological and psychiatric symptoms.